ITGAX and neoplasm: Our previous work has demonstrated that β-catenin activation in CD11c+ DCs suppresses antitumor immunity, as CD11c-β-cateninactive mice in which the GSK-3β phosphorylation site (exon3) of β-catenin was deleted in CD11c+ DCs displayed significantly enhanced tumor growth [3].